Reports
Comprehensive perspectives on critical issues
Deloitte Recap publishes periodic reports on key issues related to biopharma partnership and licensing issues. By taking advantage of our database of deals, our analysts explore a variety of market segments and trends from every available perspective in order to glean the critical insights that power smarter decisions. Browse our archive of reports below.
Oncology Deal Making & Development Trends, 2008-2012
Single User Copy: USD $2,995
Site License Copy: USD $6,995
Global Site License Copy: USD $9,995
April 2013
HIGHLIGHTS:
- From 2008-2012, Phase II oncology assets earned a median upfront fee of $31.5 million for sellers, a 142% jump from Phase I and the highest step-up at any stage.
- Overall, oncology licensing activity between 2008-2012 shows a dominant and sustained focus on early stage (Discovery through Phase I) assets: About 70% of deals in each of the five years were for early stage assets.
- Oncology M&A trends mirror the focus on early stage assets: 30% of oncology target companies had pre-Phase II development stage products versus just 15% of non-oncology targets.
- The median announced deal size for oncology licenses and joint ventures from 2008-2012 was $334 million (average: $417 million), which ranked it as the second highest therapeutic area in terms of deal size after Autoimmune/Inflammatory (median: $405 million, average: $492 million).
With a Special Section on Risk Mitigation Tools Used in Co-Development Deals
Single User Copy: USD $2,995
January 2013
The Deloitte Recap of 2012 Deals provides analyses and key data on 1,692 publicly announced deals in 2012 (463 of which had disclosed an aggregate value of $115 billion). This report provides insights into licensing activity and M&A trends plus a special section on risk mitigation tools used in co-development deals. Also included is an Excel spreadsheet of the 1,692 transactions indexed by over 45 different criteria that enable advanced sorting and analysis. The report includes 23 charts and tables and 29 proprietary deal snapshots that can be easily inserted into reports and presentations. Read more.
Special Focus on Therapeutic Products Companies
User License: USD $796
July 2012
Biopharma M&A deals in context: This concise 45 page report provides the context and analysis of biopharma M&A deals from 2005 to 2011 with a special emphasis on therapeutic products companies. In addition, a spreadsheet of M&A deal details can be used for additional analyses and selected deal snapshots can be easily inserted into your reports and presentations.
Biopharma Product & Technology Deal Analysis
User License: USD $796
May 2012
In this report, we analyze all product and technology deals from 2011 involving an exchange of rights or joint ventures, providing a comprehensive view of deal making trends in the biopharma industry. In addition, a spreadsheet of deal details can be used for additional analyses and deal snapshots of over 100 top deals can be easily inserted into your reports and presentations.
Therapeutic Monoclonal Antibodies - Insights, Strategies and Data, Part One
User License: USD $760
How U.S. Biotechnology Companies Pioneered the Path to Clinical, Regulatory and Market Success for Monoclonal Antibodies—May 2011
Monoclonal Antibodies (mAbs) have experienced a rapid rise in importance in the biopharma industry, with $36B in sales in 2011. In part one of this special two-part report, we profile the key development metrics for mAbs, and illuminate the strategies of successful mAb companies as they navigate to clinical, regulatory, and market success.
Therapeutic Monoclonal Antibodies - Insights, Strategies and Data, Part Two
User License: USD $995
What's the Deal with Monoclonal Antibodies?—August 2011
In Part Two of our report on Monoclonal Antibodies, we explore the key drivers of deal value when it comes to mAbs with profiles of key companies and pipelines, benchmarks of deal milestone payments, and the most valuable clinical areas.
Buy-Side Due Diligence - Potential Deal Encumberments
User License: FREE
Alliance Revenues and Liabilities of a Potential Acquisition Target
When conducting buy-side due diligence and valuing a potential acquisition target company, encumberments to the deal might include contractual change of control provisions affecting partnered products, changes in governance, and the value of active alliance revenues and liabilities in the form of milestone payments and royalties that the target is party to.
Innovative Strategies for Oncology Drug Development
User License: FREE
How Biotech Companies Have Won a Growing Share of Oncology Drug Approvals
This white paper highlights how biotech companies operating on lean R&D budgets have successfully produced a significant number of first-in-class compounds and $1 billion-plus drugs.
Related Links
- Recap IQ
- Increase the speed and power of your dealmaking with the deepest deal and pipeline content available.
- Trendlines
- How important are partnerships to the success of a drug? Find out now with a free subscription to Trendlines.
- Mobile Updates
- Get targeted updates sent directly on your iPhone and iPad with Recap Scout.
Email